Breakthrough Medical Devices in 2026: FDA vs. EU Frameworks, Global Fast-Tracks and Commercialization Realities

A new era of breakthrough medical devices gives manufacturers a real strategic opening: earlier regulator engagement, prioritized review and, in some markets, faster routes to payment. The United States has run its Breakthrough Devices Program since 2016. The European Union now has its own framework, set out in MDCG guidance in December 2025, and a European Medicines Agency pilot that opened on 28 April 2026.

This guide compares the two, reviews other fast-track initiatives, and uses AI diagnostics and neurostimulation as worked examples. The short version: both systems speed up regulatory dialogue, and neither one guarantees coverage or payment.

What the FDA Breakthrough Devices Program offers

The FDA Breakthrough Devices Program is set out in section 515B of the Federal Food, Drug, and Cosmetic Act, added by the 21st Century Cures Act. It covers devices and device-led combination products reviewed through the 510(k), De Novo or PMA pathways.

A device qualifies when it provides more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition, and meets at least one more criterion: it is a breakthrough technology, no approved or cleared alternative exists, it offers significant advantages over existing alternatives, or its availability is in the best interest of patients. FDA's Breakthrough Devices Program guidance explains the criteria and the process. Manufacturers request designation through the Q-Submission program before submitting a marketing application.

Designated devices get more interactive communication with FDA, sprint discussions on specific topics, the option of a data development plan, and prioritized review. The marketing standard does not change. A breakthrough device still needs a 510(k), De Novo or PMA decision on the usual safety and effectiveness standard.

What the EU breakthrough framework and pilot add

Under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), the Medical Device Coordination Group published MDCG 2025-9, Guidance on Breakthrough Devices in December 2025. It describes breakthrough criteria built around significant positive clinical impact, life-threatening or irreversibly debilitating conditions, and comparison with available alternatives and the state of the art. It also covers clinical evidence, post-market clinical follow-up and the role of the expert panels.

The European Medicines Agency then launched a breakthrough devices pilot on 28 April 2026. Manufacturers ask the medical device expert panels for an opinion on breakthrough status. Designated devices get enhanced regulatory support, including priority scientific advice from the panels. According to the EMA pilot page, the pilot runs in three phases until 2027, subject to resources. Phase one is open to class III devices and class IIb active devices that administer or remove medicines. Later phases are planned for other device types, including IVDs.

Certification still runs through a notified body. The EU framework adds structured early advice; it does not create a separate approval route or lower MDR or IVDR requirements. The European Commission has also proposed a revision of the MDR and IVDR to simplify procedures and support innovation, so check the current legislative status before building it into a plan.

FDA versus EU: where they align and diverge

**Common ground.** Both programs target serious conditions and unmet needs, both reward early and structured dialogue, and neither lowers the evidence bar. Both lean on post-market evidence to manage uncertainty at launch.

**Main divergences.** FDA designation comes from a single regulator that also makes the marketing decision. In Europe, the expert panels advise while a notified body certifies, so manufacturers must keep two parties aligned. The FDA program covers all risk classes that use 510(k), De Novo or PMA, while the EU pilot starts with high-risk devices. The biggest commercial difference is payment: a US designation can make a device eligible for Medicare's TCET pathway, but EU designation has no direct link to national reimbursement.

Other initiatives that support breakthrough devices

• **United Kingdom.** The MHRA's Innovative Devices Access Pathway (IDAP) pilot selected eight technologies for coordinated regulatory and access support from the MHRA, NICE, NHS England and the Welsh and Scottish health technology bodies. The pilot is now closed to new applications.
• **Japan.** The Ministry of Health, Labour and Welfare's SAKIGAKE designation can give innovative devices prioritized consultation and review by the PMDA.
• **Germany and France (digital devices).** Germany's DiGA fast-track allows provisional listing of digital health applications while evidence is gathered, and France's PECAN offers early, temporary coverage for qualifying digital devices. Our international reimbursement pathways guide compares these routes.
• **United States payment.** Medicare's Transitional Coverage for Emerging Technologies (TCET) pathway is limited to FDA-designated Breakthrough Devices. CMS anticipates up to five per year, with a goal of finalizing a national coverage determination within six months after FDA authorization.

Our October 2026 MedTech Pulse also reported that CMS repealed the alternative pathway that let Breakthrough Devices qualify for supplemental hospital payment without separately showing substantial clinical improvement. Designation now buys less on the payment side, so payer-ready evidence matters more.

Example 1: AI diagnostics

AI diagnostic tools often fit breakthrough criteria when they find serious disease earlier or where specialists are scarce. The autonomous diabetic retinopathy system IDx-DR, now marketed as LumineticsCore, received Breakthrough designation and De Novo authorization in 2018. It is a common reference point for autonomous AI.

Regulatory speed has not translated into easy payment for most AI tools. Many still lack dedicated codes, as we covered in why only 16 AI procedures have CPT codes and AI-enabled devices that are cleared but not paid. For AI diagnostics, plan for:

• **Clinical utility, not only accuracy.** Payers want to see that results change care and outcomes, not just sensitivity and specificity.
• **Change management.** A predetermined change control plan lets you update models in the US without a new submission for each planned change. In the EU, discuss significant-change expectations with your notified body early.
• **EU AI Act overlap.** AI medical devices that need notified-body review are also treated as high-risk AI systems under the EU AI Act, which adds data governance and transparency duties.
• **Workflow and integration.** Hospitals often stall on EHR integration even after committee approval. See why AI devices stall after VAC approval.

Example 2: Neurostimulation

Neurostimulation devices often target serious, irreversibly debilitating conditions, so they fit the core breakthrough test well. Two US examples:

• The Vivistim Paired VNS System, which pairs vagus nerve stimulation with rehabilitation for upper-limb function after ischemic stroke, held Breakthrough designation and received FDA PMA approval in 2021.
• ONWARD Medical's ARC-EX system, a non-invasive spinal cord stimulation device for hand and arm function after spinal cord injury, held Breakthrough designation and received De Novo authorization in December 2024.

For implantable neurostimulators, the EU pilot's first phase is directly relevant because active implantable devices are class III under the MDR. Class III implantables are also within scope of joint scientific consultation under the EU HTA Regulation, which the EMA notes can run in parallel with expert panel advice. Plan for:

• **Long-term outcomes.** Payers and HTA bodies weigh durability of benefit, reoperations, battery replacement and device-related adverse events.
• **Comparators.** Define current care, such as medication, rehabilitation alone or an existing stimulator, in terms payers recognize.
• **Coding and site of service.** Implant procedures, programming visits and replacement generators each need a coding and payment path. Our budget impact models guide shows how to present costs to hospitals.

How to use breakthrough status strategically

1. **Decide early.** Request designation before the pivotal protocol is locked, so dialogue can still shape the study. 2. **Design one evidence plan for regulators and payers.** Use our dual-intent clinical evidence guide and its free worksheet to map each endpoint to FDA, notified-body and payer needs. 3. **Sequence the markets.** Compare FDA and EU timelines with national reimbursement routes. Our CE mark vs FDA clearance guide covers the basics. 4. **Budget for post-market evidence.** Both systems rely on it, and payers will ask for it. 5. **Treat designation as a starting point.** As our article on why clearance is easy and payment is hard explains, commercial success depends on coverage, coding and hospital adoption.

Free and premium planning workbooks are on the toolkits page, including the Reimbursement & Coding Roadmap and Hospital VAC Dossier Pack. To compare reimbursement routes across markets, use MedTech Compass. For help drafting designation requests and evidence summaries, explore Cahir MedTech Copilot. Keep qualified regulatory, clinical and reimbursement review in the process.

Breakthrough medical devices: quick answers

What is the FDA Breakthrough Devices Program?

It is a voluntary FDA program for devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions. Designated devices get more interactive communication and prioritized review, but the marketing standard does not change.

Does the EU have a breakthrough devices program?

Yes. MDCG 2025-9, published in December 2025, sets out a breakthrough devices framework under the MDR and IVDR. The EMA launched a pilot on 28 April 2026 that gives designated devices priority scientific advice from the expert panels.

What is the biggest difference between the FDA and EU programs?

FDA both designates and authorizes the device. In the EU, expert panels give the breakthrough opinion and advice, while a notified body certifies the device. EU designation also has no direct link to reimbursement.

Does breakthrough designation guarantee Medicare coverage?

No. Designation can make a device eligible for Medicare's TCET pathway, which CMS expects to accept up to five devices per year, but coverage still depends on evidence that the device is reasonable and necessary.

Which devices can join the EU pilot first?

Phase one is open to class III devices and class IIb active devices intended to administer or remove medicines. Later phases are planned for other device types, including IVDs.

Are AI diagnostics and neurostimulation devices good breakthrough candidates?

Often, when they address serious conditions with limited alternatives. Examples include IDx-DR for diabetic retinopathy and the Vivistim and ARC-EX neurostimulation systems. Payment still needs separate evidence of clinical utility and value.

Sources

• FDA: Breakthrough Devices Program
• FDA: Breakthrough Devices Program guidance
• MDCG 2025-9: Guidance on Breakthrough Devices
• EMA: New pilot to support development of breakthrough medical devices (28 April 2026)
• EMA: Expert panel support for breakthrough medical devices pilot
• CMS: Transitional Coverage for Emerging Technologies final notice
• MHRA: Innovative Devices Access Pathway